Description: Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient's body. The dCELL has applications in wound care, heart valve replacement and knee repair. Its products portfolio includes DermaPure, which is used for the treatment of chronic or acute wounds; SurgiPure XD Surgical Tissue Matrix, which is used as a soft tissue patch for the surgical repair of damaged or ruptured soft tissue membranes; OrthoPure XM, which is used to replace the tissue removed during a partial meniscopy; OrthoPure XT, which is a decellurised porcine tendon, and CardioPure, a decellurised human pulmonary or aortic heart valve.
Home Page: www.tissueregenix.com
TRX Technical Analysis
Unit 3
Garforth,
LS25 2GY
United Kingdom
Phone:
44 33 0430 3052
Officers
| Name | Title |
|---|---|
| Mr. Daniel R. Lee | CEO & Director |
| Mr. David Claiborne Cocke | CFO & Exec. Director |
| Ms. Christine Rowley | Technical & Operations Director |
| Ms. Kirsten Lund | Group Fin. Director & Company Sec. |
| Prof. Eileen Ingham | Consultant |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 54.0541 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.559 |
| Price-to-Sales TTM: | 1.8748 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 79 |